Research programme: NanoBiodrugs - Nanobiotix

Drug Profile

Research programme: NanoBiodrugs - Nanobiotix

Alternative Names: NanoBiodrug; Nanodrugs; NanoMag; NanoPDT; NanoXray; NBTX-IV; NBTX-TOPO; Nbtxr

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanobiotix
  • Class
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
  • 30 Jun 2013 Nanobiotix selects a lead candidate in its NBTX IV programme
  • 26 Jun 2013 Nanobiotix enters into a collaboration with the National Cancer Institute for the development of NBTX IV in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top